PillRx only · Injection, Solution · Intravenous
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride
7 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US27 NDCs
7 active makers
7 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
5.5K
Rx · 2026 Q1
229K
Units dispensed
-28%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it7 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | unknown | 10 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 8 | SUPPLYING |
| Fresenius Kabi USA, LLC | unknown | 4 | SUPPLYING |
| Actavis Pharma, Inc. | unknown | 4 | SUPPLYING |
| Gland Pharma Limited | unknown | 3 | SUPPLYING |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | unknown | 2 | SUPPLYING |
| Sagent Pharmaceuticals | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Nov 17, 2020RECALLRecall (Class III): DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only…
Cross Contamination with Other Products: trace amounts of octreotide found during testing — Recalling firm: Fresenius Kabi USA, LLC — Nationwide USA and Puerto Rico